The joint review, titled "New Insight into RNA Biomarkers in Neuropathic Pain," focuses on translating molecular science into practical clinical tools. The authors examine specific RNA modifications, such as N6-methyladenosine, to identify reproducible molecular changes that correlate with pain severity and treatment efficacy. By shifting the focus from subjective patient accounts to underlying molecular events, clinicians may gain a more precise method for selecting therapies and tracking patient responses.

Amol Soin, M.D., founder of Soin Neuroscience, noted that identifying these molecular signatures could clarify how neuromodulation therapies actually produce relief. This research stems from an ongoing partnership between the two companies, merging Lilac’s expertise in quantitative RNA workflows with Soin’s clinical background in pain management. Shreyas Shah, vice president at Lilac Biosciences, emphasized that this collaboration aims to bridge the gap between academic RNA research and actionable, clinically meaningful diagnostic tools.